Novartis CEO projects 2026 growth despite ‘largest patent expiry’ in company history Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmaker’s fourth-quarter

#Novartis #VasNarasimhan #patentexpirations #patentcliff #Entresto #Pluvicto #Kisqali #BTKinhibitors #PSMAtargetedradioligandtherapy #prostatecancer #BTKinhibitor #chronicspontaneousurticaria #multiplesclerosis #Rhapsido #relapsingMS #MS #antibodies #Bcellpathways #Kesimpta
zurl.co/n0N8z

Does Kisqali improve survival / life expectancy for mBC? Official answer: Kisqali can extend survival and the amount of time you live without HR+/HER2- advanced or metastatic breast cancer...

#Kisqali extends survival by ~1 year for HR+/HER2- advanced breast cancer, with 5-year overall survival benefits. Maintains quality of life during treatment. Also significantly reduces recurrence in high-risk stage II-III early breast cancer. Consult your oncologist.

Novartis、2025〜2030年の売上CAGRを5〜6％に上方修正 Kisqali・Scemblix含む30超の高価値候補薬が成長を牽引 | STELLANEWS.LIFE Novartisは2025〜2030年の売上成長見通しをCAGR＋5〜6％へ引き上げ、KisqaliやScemblixのピーク売上予測を上方修正。30以上の高価値候補薬と15件以上の主要試験結果が中期成長を支える計画を発表。

Novartis Raises 2025–2030 Sales Growth Outlook to +5–6% CAGR

🔗 Full article: stellanews.life/technology_c...

#Novartis #Biopharma #Kisqali #Scemblix #PharmaGrowth #R&D #Pipeline #CAGR #InvestorRelations #LifeSciences

【Novartis、2025〜2030年の売上成長率を上方修正】
ノバルティスは、2025〜2030年の売上CAGR（年平均成長率）を＋5〜6％（恒常為替ベース）に引き上げました。
成長を支えるのは、Kisqali（乳がん）やScemblix（慢性骨髄性白血病）をはじめとする30以上の高価値候補薬です。

#Novartis #Kisqali #Scemblix #製薬業界 #企業戦略 #パイプライン #R&D #医薬品市場 #株主情報

Kisqali (ribociclib) | Relatório de avaliação de financiamento público disponível na Infomed | Deferimento Infarmed

Kisqali (ribociclib) | Relatório de avaliação de financiamento público disponível na Infomed | Deferimento
swki.me/DKvf66yE

#infarmed #medicamentos #financiamentopublico #kisqali #ribociclib

#MAHA I Loved #Reagan...

good for makeres of #KISQALI
one of their #WARNING mentions is
COULD HARM #UNBORN #BABIES [in Womb]
NOT #LEFTARDS game call it #FETUS!
related items...
jlenarddetroit.substack.com/p/maha
and
jlenarddetroit.substack.com/p/maha-update

Comparative efficacy of first- versus second-line CDK4/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer - Breast Cancer Research Purpose The greater progression-free survival (PFS) improvements observed in first-line (1L) versus second-line (2L) CDK4/6 inhibitor (CDK4/6i) trials underpin current guideline recommendations establ...

It's clear that CDK inhibitors belong in the first line of treatment for HR+/HER2- breast cancer.

#ribociclib #kisqali #oncology

breast-cancer-research.biomedcentral.com/articles/10....

Does Kisqali improve survival / life expectancy for mBC? Official answer: Kisqali can extend survival and the amount of time you live without HR+/HER2- advanced or metastatic breast cancer...

#Kisqali extends survival by ~1 year for advanced HR+/HER2- breast cancer with an overall survival benefit of about 5 years. Preserves quality of life during treatment and significantly reduces recurrence risk in high-risk early breast cancer patients.

Thousands more breast cancer patients to benefit from new NHS treatment

#NICE #oncology #breastcancer #breastcancerpatients #NHStreatment #NICEapproved #ribociclib #Kisqali #Novartis #earlystagebreastcancer #NICEfinaldraftguidance #aromataseinhibitor #hormonereceptorpositiveHER2negativeearlybreastcancer #Milestoneforbreastcancercare
www.nice.org.uk/news/article...

#novartis #kisqali #full-year-earnings-forecast #second-quarter-sales #us-tariff-threat #tariff-hike #prescription-drug #pharmaceutical-industry #drugmaker #earnings-outlook #2025-economy #samsung-swiss #market-outlook #income-guidance

What are the benefits of taking Kisqali and Femara together? Official answer: Taking Kisqali and Femara together can benefit patients with specific types of breast cancer because the medications...

For breast cancer patients the combination of #Kisqali and #Femara often works better than just Femara alone!
✨ Kisqali stops cancer cells from growing
✨ Femara reduces estrogen that can feed cancer growth.

Does Kisqali improve survival / life expectancy for mBC? Official answer: Kisqali can extend survival and the amount of time you live without HR+/HER2- advanced or metastatic breast cancer...

#Kisqali for advanced/metastatic cancer: Adds about 1 year more survival time, patients typically live around 5 years overall, and helps maintain quality of life during treatment. For early-stage cancer, Kisqali significantly reduces the risk of cancer coming back.

Novartis' Kisqali Shows Key Data in Reducing Breast Cancer Recurrence Rates Novartis' latest data reveals Kisqali's significant impact on reducing distant recurrence in early breast cancer patients. Understanding its benefits is key.

Novartis' Kisqali Shows Key Data in Reducing Breast Cancer Recurrence Rates #USA #Breast_Cancer #Novartis #East_Hanover #Kisqali

Blue Sky asks “What’s up?” again. And my answer hasn’t changed. My liver enzymes went up more in the past 5 days. Livers are so high maintenance, sheesh! 🤨 #kisqali #mbc #stage4 #breastcancer #cansky

ノバルティス、第3四半期売上高10％増、堅調な業績を継続し通期予想上方修正 製薬大手ノバルティスが2024年第3四半期の決算を発表。売上高は10％増、コア営業利益は20％増と大幅増益。主力製品の好調に加え、米国での承認取得も業績を押し上げた。通期業績予想も上方修正され、今後の成長に期待が高まる。

ノバルティス、第3四半期売上高10％増、堅調な業績を継続し通期予想上方修正 #ノバルティス #Kisqali #Pluvicto

製薬大手ノバルティスが2024年第3四半期の決算を発表。売上高は10％増、コア営業利益は20％増と大幅増益。主力製品の好調に加え、米国での承認取得も業績を押し上げた。通期業績予想も上方修正され、今後の成長に期待が高まる。

FDA genehmigt Novartis-Medikament Kisqali für weitere Indikation Von dpa-AFX FDA genehmigt Novartis-Medikament Kisqali für weitere Indikation

Die 🇺🇸 US-Gesundheitsbehörde FDA hat das #Novartis, Medikament #Kisqali für die Behandlung von Patientinnen mit einer bestimmten Form von Brustkrebs im Frühstadium zugelassen.

de.investing.com/news/stock-m...